Tarunendu Dwivedi, MD
Psychiatry · Rock Hill, SCNPI 1063481844
Payments from drug & device makers
Across 127 payments — averaging $32.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$588
- Teva Pharmaceuticals USA, Inc.$532
- Sunovion Pharmaceuticals Inc.$493
- Ironshore Pharmaceuticals Inc.$438
- Tris Pharma Inc$405
- Johnson & Johnson$291
- plus $1K from 14 others
What the payments were for
- Food & beverage$3,83793%
- Education$2747%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 27 | $588 |
| Teva Pharmaceuticals USA, Inc. | 11 | $532 |
| Sunovion Pharmaceuticals Inc. | 7 | $493 |
| Ironshore Pharmaceuticals Inc. | 12 | $438 |
| Tris Pharma Inc | 13 | $405 |
| Johnson & Johnson | 5 | $291 |
| Otsuka America Pharmaceutical, Inc. | 6 | $251 |
| Neos Therapeutics, LP | 12 | $229 |
| Neurocrine Biosciences, Inc. | 10 | $183 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $158 |
| Eisai Inc. | 1 | $122 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $96 |
| Axsome Therapeutics, Inc. | 2 | $86 |
| Corium, LLC | 4 | $74 |
| Supernus Pharmaceuticals, Inc. | 3 | $62 |
| Shire North American Group Inc | 2 | $35 |
| Adlon Therapeutics L.p. | 1 | $20 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| Jazz Pharmaceuticals Inc. | 1 | $16 |
| Collegium Pharmaceutical, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LATUDA$361
- VRAYLAR$345
- SPRAVATO$243
- Dyanavel XR$242
- Jornay PM 20mg capsules (Bottle of 100)$238
- CAPLYTA$128
- AUSTEDO$125
- Dayvigo$122
- REXULTI$105
How this compares
$4,111 in reported general payments places this provider in the 85th percentile of 624 psychiatry providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 36 | $287,944 |
| AustedoDeutetrabenazine | 24 | $164,662 |
| VraylarCariprazine Hcl | 23 | $34,478 |
| Paliperidone ErPaliperidone | 52 | $32,433 |
| Invega SustennaPaliperidone Palmitate | 14 | $25,867 |
| Risperdal ConstaRisperidone Microspheres | 21 | $24,280 |
| LybalviOlanzapine/Samidorphan Malate | 13 | $20,231 |
| Divalproex Sodium | 316 | $19,054 |
| Quetiapine Fumarate | 466 | $19,028 |
| Divalproex Sodium ErDivalproex Sodium | 203 | $18,243 |
| Risperidone | 758 | $14,460 |
| Aripiprazole | 331 | $13,753 |
| Trazodone Hcl | 467 | $9,697 |
| Clozapine | 56 | $9,252 |
| BelsomraSuvorexant | 13 | $6,155 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $183 | $287,94436 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $532 | $164,66224 claims |
| Johnson & JohnsonInvega Sustenna, Risperdal Consta | $291 | $50,14735 claims |
| AbbVieVraylar | $588 | $34,47823 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 624 psychiatry providers in South Carolina.
Other psychiatry in Rock Hill
- Jagdish ShahRock Hill$320K
- Brian MikaRock Hill$22K
- Jacobo MintzerCharleston$4.9M
- Paul RobbinsSummerville$1.2M
- Brittany AlbrightMount Pleasant$691K
- Eduardo CifuentesCharleston$675K
- Veronica RidpathFlorence$364K
- Mark GeorgeCharleston$332K
- Ricardo FermoCharleston$262K
- John DewittAiken$221K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.